This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1479 entries already.
Pentixapharm Holding AG published new clinical Phase II data on its radiodiagnostic agent [68Ga]Ga-Pentixafor in early February. As the Berlin-based company reported, the results published in the Journal of Nuclear Medicine confirm the potential of Pentixafor PET/CT as a non-invasive alternative to adrenal venous sampling (AVS) for the subtyping of primary aldosteronism.
PharosAI, a U.K. cancer research consortium bringing together King’s College London, Queen Mary University of London, Guy’s and St Thomas’ National Health Service (NHS) Foundation Trust and Barts Health NHS Trust, has partnered with 10x Genomics to generate large-scale multimodal cancer datasets from archived NHS tumor samples using 10x’s Xenium spatial biology platform.
Swedish biotech Cereno Scientific today announced the expansion of its clinical development program for its investigational small-molecule therapy, CS014, targeting rare lung diseases.
French biotech Poxel is trying to stabilise its business after judicial reorganisation, with its court-approved recovery plan now moving into the execution phase. The Lyon-based company, which has spent the past year under financial pressure, received approval from the Commercial Court of Lyon last week to restructure its debt and continue operations.
The Göttingen-based life science group Sartorius AG closed the 2025 financial year, based on preliminary figures, with a marked increase in revenue and earnings. Group sales grew by 7.6% at constant exchange rates to around EUR 3.54 billion, while the operating EBITDA margin rose by 1.7 percentage points to 29.7%.
Newly formed French biotech Kahimmune Therapeutics has signed an exclusive licensing agreement with Gustave Roussy and SATT Paris-Saclay, securing rights to a technology platform designed to identify tumor antigens derived from the “dark” or non-coding genome. The spin-off, created in late 2025, plans to use the licensed technology to develop shared mRNA cancer vaccines, with an initial program targeting colorectal and pancreatic cancer.
French biopharmaceutical company Ipsen has entered a global collaboration and option agreement with San Diego-based biotech Origami Therapeutics to advance a small-molecule protein degrader program targeting a rare, inherited neurodegenerative disorder. The deal strengthens Ipsen’s early-stage neuroscience pipeline while giving Origami a potential path toward global development and commercialization
Paris-based drugmaker Sanofi closed 2025 with strong growth and upbeat guidance, but its latest results also reveal sharp pipeline cuts that underline a tougher phase for R&D choices.
CDMOs are currently setting the agenda across the industry. Alongside peers such as Vetter, Lonza has now delivered a clear statement of intent: strong results, sharper focus and an even more determined commitment to its core business. But the stronger investment strategy internationally frightens Switzerland – at least some analysts.
With an initial investment of around €480 million, Ravensburg-based Vetter Pharma has now fleshed out its plans to expand operations in Saarlouis, Saarland. The former automotive site is to be redeveloped by 2031 and is expected to employ up to 2,000 people in contract development and manufacturing.